Title
Category
Credits
Event date
Cost
Diagnosis and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Acute Myelogenous Leukemia
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Despite the rarity of blastic plasmacytoid dendritic cell neoplasm (BPDCN), it is crucial for the disease to remain in the differential diagnosis of neoplastic and non-neoplastic skin lesions and rashes, including leukemia cutis, as the disease can disseminate rapidly without therapy. The preferred treatment option for BPDCN is the CD123 targeted therapy tagraxofusp ersz. Tagraxofusp-ersz can be associated with potentially life-threatening capillary leak syndrome, and it is crucial to be aware of management strategies if utilizing this agent.
Evaluation and Treatment of Primary Central Nervous System Lymphoma
  • CNS Cancers
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Neuroradiologic evaluation, an important part of diagnosis and evaluation of the effectiveness of subsequent therapy, can be confounded by steroids administration used to alleviate symptoms of primary central nervous system lymphomas (PCNSL). These confounding, non-diagnostic results can delay therapies for PCNSL, which commonly consist of methotrexate-based induction and consolidation treatments. Even with therapy, more than half the cases will relapse or be refractory to therapy.
Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma
  • Non-Hodgkin's Lymphoma
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Follicular lymphoma (FL) is characterized by multiple recurrences requiring retreatment. In recent years, EZH2 inhibitors and chimeric antigen receptor (CAR) T-cell therapies have been approved for relapsed/refractory FL after ≥2 prior systemic therapy regimens. Bispecific antibodies represent a novel treatment option for heavily pretreated FL, including disease relapse following CAR T-cell therapy.
Management of TP53 Mutated Mantle Cell Lymphoma
  • Non-Hodgkin's Lymphoma
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Classical mantle cell lymphoma (MCL) with TP53 mutation is associated with inferior survival outcomes to induction chemoimmunotherapy and autologous hematopoietic cell transplant, especially in younger patients. Recent data have shown that BTK inhibitor-based regimens result in favorable outcomes in patients with previously untreated classical MCL with TP53 mutation. Chimeric antigen receptor (CAR) T-cell therapy also results in favorable response rates in previously treated classical MCL with TP53 mutation.
Chronic Myeloid Leukemia: How to Treat During Pregnancy
  • Systemic Light Chain Amyloidosis
  • 0.25 AAPA Category 1 CME credit
  • 0.25 ACPE contact hours
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 ANCC contact hours
  • 0.25 Participation
$0.00
Chronic myeloid leukemia (CML) can affect individuals of reproductive age, and tyrosine kinase inhibitor (TKI) therapy is known to have teratogenic effects. Discontinuing TKI therapy during pregnancy poses a risk of recurrence. Shared decision making is recommended in the management of patients with CML during pregnancy. Options for fertility preservation and alternatives to TKI therapy should be discussed with all patients.
The Role of JAK Inhibitors in the Management of Myelofibrosis
  • Myeloproliferative Neoplasms
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Allogeneic hematopoietic cell transplant is the only potentially curative treatment option resulting in long-term remissions for patients with myelofibrosis (MF), but it is associated with a significant rate of transplant-related complications and morbidity in patients with lower-risk MF. Patients have a significant symptom burden and a propensity for disease transformation to accelerated and blast phases. For many years, ruxolitinib was the only FDA-approved drug for the treatment of intermediate-risk or high-risk MF. Since then, multiple new JAK inhibitors have been approved by the FDA.
Amyloidosis: Diagnosis, Treatment, and Supportive Care
  • Systemic Light Chain Amyloidosis
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
High rates of early mortality in newly diagnosed systemic light-chain amyloidosis (SLCA) suggest that there continues to be a delay in early diagnosis. The initial evaluation must confirm the diagnosis, establish the extent and sites of disease, and evaluate for comorbidities that are likely to have an impact on prognosis and treatment options. Many of the novel agents used in the treatment of multiple myeloma are being utilized in the treatment of SLCA, and the treatment armamentarium is growing.
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities. Although these toxicities are generally reversible, early recognition and implementation of an appropriate management strategy are essential.
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies. Bispecific antibodies represent a novel immunotherapy approach with remarkable efficacy for the treatment of relapsed/refractory hematologic malignancies. However, they also have a distinct toxicity profile associated with T-cell activation.
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
While blinatumomab has been utilized in the setting of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) for years, emerging data has shown promising clinical efficacy with its use as post-remission therapy. Knowledge of key trial findings regarding blinatumomab consolidation for both Philadelphia chromosome-positive and Philadelphia chromosome-negative B-ALL may allow providers to choose up-front regimens with the ability to improve rates of molecular response and overall survival.

Pages